COMPANY

Epicrispr Biotechnologies

HQ: South San Francisco, CA source · epicrispr.com ↗ · West Coast

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Facioscapulohumeral Muscular Dystrophy EPI-321

Raises and deals from press releases

Raise Series C · $90M · announced Aug 11, 2026 Company release ↗
Source quote
- Aug 11, 2026 · Company release ↗
  “– Epicrispr Biotechnologies , a clinical-stage biotechnology company pioneering programmable epigenetic medicines, today announced the closing of a $90 million oversubscribed Series C financing co-led by Octagon Capital and Janus Henderson Investors”

Raises announced in these releases: $90M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Aug 11, 2026 Raise Private equity round — Series C: $90M (total, as published), announced Aug 11, 2026. Source: company's own press page. source ↗ · Form D filed Aug 26, 2026 SEC Form D ↗
Aug 11, 2026 Raise Series C · $90M source ↗
May 8, 2025 Trial start Phase 1/Phase 2: A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy source ↗
Mar 26, 2025 Raise Private equity round — Series B: $68M (total, as published), announced Mar 26, 2025. Source: company's own press page. source ↗

Jul 7, 2027 (ESTIMATED) · Phase 1/Phase 2 · A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy · NCT06907875

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $158.0M. Last 2 years.

Aug 11, 2026 Private equity round — Series C: $90M (total, as published), announced Aug 11, 2026. Source: company's own press page. source ↗ · Form D filed Aug 26, 2026 SEC Form D ↗
Mar 26, 2025 Private equity round — Series B: $68M (total, as published), announced Mar 26, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06907875	A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy	Phase 1/Phase 2	Active, not recruiting	May 8, 2025	Jul 7, 2027 (estimated)